Physician profile
Robert S Rossi
NPI 1518918317
$4,247.27
in general payments reported to CMS, 2019-2025
12 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $2,860 · 2021: $229 · 2022: $103 · 2023: $235 · 2024: $333 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $1,960.23 | 2020 | |
| Boston Scientific Corporation | $901.46 | 2019-2025 | Intracept Rf Probe, General - Pain Management, Wavewriter Alpha Prime 16 |
| Wardlow Enterprises | $872.03 | 2020 | |
| Pfizer INC. | $165.10 | 2019 | |
| Biotronik Nro, INC. | $110.88 | 2023 | Biotronik |
| Allergan, INC. | $74.49 | 2019-2021 | |
| Abbvie INC. | $58.60 | 2021-2024 | Qulipta, Ubrelvy |
| Nevro Corp. | $34.78 | 2022 | |
| Abbott Laboratories | $23.68 | 2023 | Eterna |
| Averitas Pharma INC. | $19.70 | 2023 | Qutenza |
| Celgene Corporation | $13.68 | 2019 | |
| Grt US Holding, INC. | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rossi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.